3篇
您的检索式：作者名="Steven M.Larson"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma显示文摘 | MichaelRivera Ronald A.Ghossein HeikoSchoder DanielGomez Steven M.Larson R. MichaelTuttle | 2008 | Cancer2008，，1： | 1 |
| 2 | Prospective evaluation of ^(18)F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases显示文摘Background:Despite considerable advances in preoperative imaging,up to one-third of patients operatively explored for hepatic colorectal metastases are unexpectedly found to harbor unresectable intrahepatic or extrahepatic disease.Methods:The current study is a prospective,blinded study comparing utility of[18F]2-fluoro-2-deoxyglucose positron emission tomography(18F-FDG-PET)to computed tomography(CT)and CT arterial portography(CTAP)as preoperative staging.Results:The 125 planned subjects were enrolled.Findings seen on FDG-PET alone changed therapy for 23 of 125 patients(18%).FDG-PET confirmed other radiologic findings in 16 cases(13%),for an overall influence on therapy in 39 cases(31%).FDG-PET was the most sensitive diagnostic imaging test for extrahepatic cancer;it was 80-90%sensitive for extrahepatic cancer and 70-90%specific.For the 28 cases of unresectable disease due to extrahepatic disease,FDG-PET findings solely changed therapies in 16 cases(57%)and influenced therapy in seven other cases(25%).Of the 21 unresectable cases due to extent of intrahepatic disease,FDG-PET did not solely change therapy in any.Overall,FDG-PET had the lowest sensitivity for hepatic sites compared with CT or CTAP.In particular,small(<1 cm)liver tumors were particularly poorly detected by FDG-PET.The area under the receiver operating characteristic(ROC)curve for small tumors was 0.58 and for patients on chemotherapy it was 0.66,a modest improvement over no imaging.Conclusions:FDG-PET is an important test for preoperative staging of patients with hepatic colorectal metastases,affecting treatment decisions in nearly one-third of patients.The high yield is due mainly to detection of extrahepatic disease.It is therefore recommended in patients with extrahepatic lesions suspected to be disseminated cancer or those with high risk for extrahepatic disease.It is not a good test for identification of small tumors in the liver. | Tim Akhurst Mithat Gönen Raymond E.Baser Lawrence H.Schwartz Scott Tuorto Lynn A.Brody Anne Covey Karen T.Brown Steven M.Larson Yuman Fong | 2022 | Hepatobiliary Surgery and Nutrition2022，11，4： | 1 |
| 3 | 预靶向:放射免疫治疗的进阶之路显示文摘预靶向放射免疫诊断(PRID)和预靶向放射免疫治疗(PRIT)旨在利用药用放射性核素有效标记抗肿瘤靶向抗体而分别应用于提高肿瘤显像的对比度和肿瘤治疗指数(TI)。与传统的放射性免疫偶联物不同,预靶向策略将肿瘤靶向步骤与有效载荷步骤分开,在减少正常组织暴露的同时提高了肿瘤的摄取量。预靶向策略的关键参数除了对比度和TI外,还包括抗体的免疫原性和特异性、放射性核素的适用性以及在临床中使用的便利性。预靶向的每个步骤都可以单独优化,且作为模块化系统,预靶向策略可广泛地应用于不同的肿瘤靶点、肿瘤类型或放射性核素。然而,尽管预靶向的多功能性为肿瘤的诊疗提供了巨大的应用潜能,但其过程复杂,在临床转化及如何在患者体内达到最佳使用效果方面面临着较大的挑战。该文旨在简要回顾预靶向策略的起源和发展过程,重点阐述目前已被广泛研究的2种蛋白质递送系统(生物素-链霉亲和素及半抗原-双特异性单克隆抗体)、放射性半抗原和放射性核素。此外,该文还将重点阐述预靶向研究领域的创新成果,包括使用生物正交化学和新型蛋白质载体(如自组装-解组装蛋白质和亲和体分子)进行的预靶向。该文并不是对过去30年PRID和PRIT全面的回顾,而是突出阐述了预靶向发展过程中的里程碑成果,并从TI和毒性方面评价其在临床前模型和临床试验中的应用。相信预靶向策略能够帮助人们认识肿瘤临床诊疗一体化实施的障碍,重新激发人们对放射免疫疗法的兴趣,并指导预靶向研究的进一步发展。 | 葛雨秋(译) 付海田(译) 郁春景(审校) Sarah M.Cheal Sebastian K.Chung Brett A.Vaughn Nai-Kong V.Cheung Steven M.Larson | 2022 | 中华核医学与分子影像杂志2022，42，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员